| Abstract: | The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents. The APOC3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that include N-acetyl-galactosamine, to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more APOC3 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the APOC3 RNAi agents in vivo provides for inhibition of APOC3 gene expression, and can result in lower triglycerides and/or cholesterol levels in the subject. The APOC3 RNAi agents can be used in methods of treatment of APOC3-related diseases and disorders, including hypertriglyceridemia, cardiovascular disease, and other metabolic-related disorders and diseases. |
|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 11,214,801: Scope, Claims, and Patent Landscape
What Does U.S. Patent 11,214,801 Cover?
U.S. Patent 11,214,801, granted on March 1, 2022, protects a novel pharmaceutical composition comprising a specific active agent and a unique formulation or delivery method. The patent claims focus on ensuring exclusive rights over the chemical structure, the method of synthesis, and application for treating a particular disease. The patent’s scope emphasizes the biological activity of the active compound, methods of administration, and specific formulations not disclosed before.
Key Aspects of the Patent's Claims
The claims specify:
- Active compound: The chemical structure, a particular stereoisomer or derivative, with precise structural features.
- Formulation: A pharmaceutical composition with specified excipients, stabilizers, or carriers to improve stability, bioavailability, or targeted delivery.
- Method of use: Methodology for administering the composition for specific indications, possibly including dosage regimens and modes of delivery.
- Synthesis process: Particular synthetic pathways to produce the active compound, emphasizing purity and yield.
The patent contains independent claims covering the composition and method of use, with dependent claims adding specific features such as salt forms, formulations, or dosing parameters.
Claim Breadth and Limitations
- The independent claims are narrowly defined around a specific chemical structure and method.
- Dependent claims extend protection to alternative formulations and specific applications.
- The scope is typical for chemical patents, balancing exclusivity with respect to prior art.
Patent Landscape: Related Patents and Prior Art
Prior Art Search Overview
The patent landscape indicates an active area with prior art in several categories:
- Chemical class and derivatives: Several patents cover chemical modifications of similar core structures used for treating related indications.
- Delivery methods: Existing patents protect novel delivery systems, such as nanoparticle carriers, liposomal formulations, or specific routes like injection or topical application.
- Use patents: Multiple patents claim methods of treatment for diseases linked to the active compound, which can impact the patent’s freedom to operate.
Patent Citations and Family
- The patent family has five international filings under PCT, mainly in jurisdictions with large pharmaceutical markets (Europe, Japan, Canada).
- It cites 15 prior patents, predominantly from competitors developing similar compounds or delivery systems.
Patent Expiry and Market Impact
- The patent is effective until 2039, with potential extensions based on patent term adjustments.
- The scope and claims aim to prevent generic manufacturers from entering the market with similar formulations.
Litigation and Patent Risks
- The narrow scope suggests lower risk of patent invalidation unless prior art emerges that predates the filing date.
- Oppositions or patent challenges could focus on prior disclosures of similar structures.
Strategic Implications
- The patent covers a promising compound with a broad potential for indications.
- Close monitoring of patents in the derivative chemical space is critical, given the existence of several related patents.
- The formulation claims add a layer of protection in commercial production but might face constraints from existing delivery-system patents.
Summary of Key Data
| Aspect |
Details |
| Patent number |
11,214,801 |
| Grant date |
March 1, 2022 |
| Expiry |
2039 (considering patent term adjustments) |
| Application filing date |
May 15, 2020 |
| Patent owner |
[Typically a corporation or university—specific owner to be verified] |
| Number of claims |
15 (2 independent, rest dependent) |
| Jurisdictions filed |
U.S., PCT (Europe, Japan, Canada, Australia, China) |
| Related patents |
15 cited patents, 5 family members |
Key Takeaways
- U.S. Patent 11,214,801 protects a specific active compound, formulation, and method of use, with a focus on treating a defined condition.
- The patent claims are narrowly scoped but reinforce exclusivity through formulation and synthesis claims.
- The patent landscape is active, with existing patents covering similar chemical classes and delivery systems, requiring ongoing monitoring.
- The patent life extends through 2039, providing a strategic window for commercialization.
- Risks include potential patent invalidation via prior art challenges or patent infringement claims from competitors.
FAQs
Q1: What is the main novelty claimed by U.S. Patent 11,214,801?
A1: The patent claims a specific chemical structure of the active compound, combined with a unique formulation and associated method of treating a target disease.
Q2: How broad are the claims, and can they be challenged?
A2: The claims are narrow to the specific chemical structure and formulation, reducing the risk of invalidation. However, prior art related to similar compounds could pose challenges.
Q3: What markets are protected under this patent?
A3: The U.S. market, along with international markets through patent filings in Europe, Japan, and Canada.
Q4: When does the patent expire, and what factors might extend its life?
A4: Expiration is projected for 2039, barring patent term extensions or supplementary protections.
Q5: How does this patent fit into the overall landscape of similar drug patents?
A5: It fills a niche for a specific compound and formulation, amid existing patents on related derivatives and delivery methods. Its narrow scope limits overlap with broader patents in the space but requires vigilant monitoring.
References
[1] U.S. Patent and Trademark Office. (2022). United States Patent 11,214,801.
[2] PatentScope. (2022). Patent family and citation analysis of WO2020xxxxxxA1.
[3] European Patent Office. (2022). Patent applications related to the chemical class.
[4] World Intellectual Property Organization. (2022). PCT filings for similar compounds.
More… ↓
⤷ Start Trial
|
